EMD Biosciences to Market siRNA, DNA Transfection Reagents from DNT | GenomeWeb
NEW YORK (GenomeWeb News) – EMD Biosciences, part of Merck KGaA’s Performance and Life Science Chemicals division, has signed an exclusive license and supply agreement with Dendritic Nanotechnologies for siRNA and DNA transfection reagents, the companies said today.
Under the terms of the agreement, DNT a US subsidiary of Australian firm Starpharma, will supply EMD Biosciences with its Priofect transfection reagents. EMD will market the reagents through its Novagen product line.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.